Australia's Vitrafy Life Sciences flat; Bell Potter raises PT on cash flows hopes
** Vitrafy Life Sciences VFY.AX trading flat at A$1.6 ** Bell Potter raises PT by 10 Au cents to A$2.10; retains "speculative buy" ** Expects higher cash flows on visibility of commercial launch timing of its VCU2 cryopreservation device in FY26 ** Views recent leadership changes positively ** Ord Minnett assigns "speculative buy", with PT of A$2.30, per data compiled by LSEG (Reporting by Nichiket Sunil in Bengaluru) ((Nichiket.Sunil@thomsonreuters.com))
Recent news on Vitrafy Life Sciences
See all newsBrief: Vitrafy Life Sciences Appoints Jan Gielen As CFO
Australia's Vitrafy Life Sciences heads for best day in 2 months on Versiti deal
Australia's Vitrafy Life Sciences gains on entering US market
Brief: Vitrafy Life Sciences Enters U.S. Cell & Gene Therapy Market With Charter Medical Agreement
Brief: Vitrafy Life Sciences Posts FY Operating Loss Of A$14.6 Million